Actos Sales Grow On Avandia's Woes, Takeda Reports
This article was originally published in PharmAsia News
Executive Summary
U.S. sales of the type 2 diabetes therapy Actos (pioglitazone) were up $117 million or 19.2 percent year over year in the first quarter of 2007, Takeda General Manager of Finance and Accounting Hiroshi Takahara reported during the company's first-quarter 2007 earnings call July 31